Table 4.
Comparison of tumor characteristics between patients with hepatocellular carcinoma with resistant chronic hepatitis B (R’ group) and hepatocellular carcinoma with chronic hepatitis B treated with antiviral treatment (N’ group): subgroup analysis based on tumor surveillance interval (≤ 6 mo) n (%)
| Variables | R’ group (n = 37) | N’ group (n = 39) | P-value |
| Gender (male) | 27 (73) | 31 (79.5) | 0.594 |
| Age (mean, yr) | 55.24 ± 7.94 | 56.08 ± 10.3 | 0.695 |
| Presence of cirrhosis | 36 (97.3) | 39 (100) | 1 |
| Portal vein thrombosis | 5 (13.5) | 8 (20.5) | 0.546 |
| Vascular invasion | 11 (29.7) | 8 (20.5) | 0.431 |
| Multi-nodular tumor type | 27 (73) | 27 (69.2) | 0.803 |
| CLIP score | 0.59 ± 0.72 | 0.97 ± 0.98 | 0.061 |
| Modified UICC stage (< IVA) | 34 (91.9) | 35 (89.7) | 1.0 |
| Modified UICC stage (I/II/III/IVA/IVB) | 11/11/12/3/0 | 11/15/9/2/2 | |
| LN involvement | 0 (0) | 2 (5.1) | 0.496 |
| Distant metastasis | 0 (0) | 1 (2.6) | 1 |
| AST U/L (median, range) | 48 (20-141) | 52 (16-481) | 0.283 |
| ALT U/L (median, range) | 38 (8-199) | 44 (11-150) | 0.14 |
| Platelet count (103/mm3) (median, range) | 101 (23-232) | 131 (24-260) | 0.059 |
| CRP (mg/dL) (median, range) | 0.3 (0-2) | 0.5 (0-16) | 0.029 |
| AFP IU/mL (median, range) | 27 (2-737) | 52 (3-16644) | 0.039 |
| Child-Pugh score | 5.51 ± 0.85 | 5.91 ± 1.32 | 0.982 |
| Duration of anti-viral Tx | 21.5 (8-72) | 7 (1-60) | < 0.001 |
| Total follow-up duration | 791.95 ± 643.06 | 1114.23 ± 646.84 | 0.033 |
UICC: Union Internationale Contre le Cancer; CLIP: Cancer of the Liver Italian Program; LN: Lymph node; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; HBV: Hepatitis B virus; CRP: C-reactive protein.